Baillie Gifford holds 4.62% of Recursion stock

Baillie Gifford & Co reports beneficial ownership of 23,774,972 shares of Recursion Pharmaceuticals, Inc. Class A common stock, representing 4.62% of the class as of December 31, 2025.

Rhea-AI Filing Summary

Baillie Gifford & Co reports beneficial ownership of 23,774,972 shares of Recursion Pharmaceuticals, Inc. Class A common stock, representing 4.62% of the class as of December 31, 2025. The firm has sole voting power over 23,730,293 shares and sole dispositive power over all 23,774,972 shares.

The filer identifies itself as an investment adviser and states the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Recursion. The filing confirms ownership has fallen to 5 percent or less of the class.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Baillie Gifford hold in Recursion Pharmaceuticals (RXRX)?

Baillie Gifford & Co reports beneficial ownership of 23,774,972 Recursion Pharmaceuticals Class A shares. This represents 4.62% of the outstanding class as of December 31, 2025, according to the Schedule 13G/A amendment filed as an institutional investment adviser.

Does Baillie Gifford control Recursion Pharmaceuticals (RXRX) through this stake?

No, Baillie Gifford certifies the shares are held in the ordinary course of business and not to change or influence control. The 4.62% Class A ownership is reported as a passive investment position under Schedule 13G/A, rather than an activist or control-focused holding.

How much voting power does Baillie Gifford have in RXRX shares?

Baillie Gifford has sole voting power over 23,730,293 Recursion Class A shares. It reports no shared voting power. It also has sole dispositive power over 23,774,972 shares, indicating exclusive authority to decide how this block is voted and disposed.

Why did Baillie Gifford file an amended Schedule 13G/A for RXRX?

The amended Schedule 13G/A reflects Baillie Gifford’s updated Recursion stake at 4.62% of the Class A shares. Item 5 indicates ownership of 5 percent or less of the class, requiring disclosure of this reduced level of beneficial ownership as of December 31, 2025.

What type of investor is Baillie Gifford in Recursion Pharmaceuticals (RXRX)?

Baillie Gifford & Co classifies itself as an investment adviser. It states the applicable foreign regulatory scheme for this investment adviser role is comparable to that of a similar U.S. institution and that it can provide additional information to Commission staff upon request.

When was Baillie Gifford’s Recursion (RXRX) ownership measured for this filing?

The ownership data in this Schedule 13G/A amendment is tied to an event date of December 31, 2025. As of that date, Baillie Gifford beneficially owned 23,774,972 Class A shares, representing 4.62% of Recursion’s outstanding Class A common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 10:04 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

RECURSION PHARMACEUTICALS, INC.

(Name of Issuer)

Class A Common Stock

(Title of Class of Securities)

75629V104

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 75629V104

1

Names of Reporting Persons

BAILLIE GIFFORD & CO

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 23,730,293.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 23,774,972.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

23,774,972.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: RECURSION PHARMACEUTICALS, INC.
(b)	Address of issuer's principal executive offices: 41S RIO GRANDE STREET, 41S RIO GRANDE STREET, SALT LAKE CITY, CALIFORNIA, 84101.
Item 2.
(a)	Name of person filing: Baillie Gifford & Co
(b)	Address or principal business office or, if none, residence: Calton Square 1 Greenside Row Edinburgh EH1 3AN Scotland UK
(c)	Citizenship: Scotland
(d)	Title of class of securities: Class A Common Stock
(e)	CUSIP No.: 75629V104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
	Investment Adviser
Item 4.	Ownership
(a)	Amount beneficially owned: 23,774,972
(b)	Percent of class: 4.62 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 23,730,293
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 23,774,972
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Investment Adviser is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BAILLIE GIFFORD & CO

Signature:	Grant Meikle
Name/Title:	Regulatory Reporting Manager
Date:	01/20/2026